含有下一代后生物的新型脂质体凝配方:特征,风病学,稳定性,释放动力学和体外抗菌活性研究
Halise Betül Gökçe1, İsmail Aslan2
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey.
Gels (Basel, Switzerland)
|November 26, 2024
概括
后生物质,即益生菌中的生物活性化合物,显示出抗菌潜力. 脂质体凝配方增强其活性和可用于制药应用的可用性.
科学领域:
- 微生物学 微生物学
- 药品制造 药品制造 药品制造
- 生物技术是生物技术.
背景情况:
- 益生菌和益生菌提供健康益处,新兴的研究突出显示了后生菌的潜力.
- 后生物质是通过益生菌发酵产生的生物活性物质,具有抗菌性质.
- 本研究重点是凝形式的脂质体后生物制剂,以增强其应用.
研究的目的:
- 为了研究在凝中配制的脂质体后生菌的抗菌作用.
- 描述和优化脂肪体系统及其凝配方.
- 评估优化配方对各种病原体的抗微生物疗效.
主要方法:
- 开发和优化含有后生物的脂质体系统.
- 脂质体和凝配方的表征 (颗粒大小,PDI,泽塔潜力,封装效率,透性,释放形状,稳定性).
- 使用磁盘扩散和微稀释方法对*Pseudomonas aeruginosa*,*Staphylococcus aureus*,*Escherichia coli*,*Enterococcus hirae*和*Candida albicans*进行抗菌活性评估.
主要成果:
- 优化的脂质体配方 (L1) 显示颗粒大小为185.32nm,PDI为0.206,泽塔电位为35.0mV,封装效率为17.52%.
- 经过6小时,透率为51.52% ,释放动力学遵循控制释放的第一顺序.
- 配方后生物体表现出与自由后生物体相比的抗菌活性.
结论:
- 脂质体凝配方有效地提供后生物质,支持它们的抗菌作用.
- 优化的脂质体凝配方 (LG1) 显示出药物应用的巨大潜力.
- 这项研究促进了对后生菌及其脂质体输送系统的理解和应用.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
155
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
155
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
163
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
163